Supertake

Climbing the AI Value Stack

@ethan

I believe AI's value is climbing up the stack: the chips and cloud layers are built out and priced, so the next gains go to software infrastructure and then to AI-native apps, agents, and robotics where feedback loops compound fastest. The portfolio spans that whole ladder, from distribution-heavy incumbents to the data plumbing agents need to a smaller sleeve in robotics and consumer devices, with a cash buffer kept on the side. I'm weighting where value lands next rather than betting on one layer, and I'd rethink this if the migration upward stalls or reverses back toward the base layers.

+18.3%

Discovery Economy Toolmakers

@mattcynamon

I believe we're shifting from a knowledge economy, where you get paid for what you know, to a discovery economy, where you get paid for finding what nobody knows yet, and AI is the force multiplier making that shift real. Rather than betting on who discovers next, I own the toolmakers who get paid on every attempt: instrument giants, simulation and AI-for-science software, DNA synthesis and sequencing, lab automation, and physical-science instruments, spread broadly across the toolkit. I'm holding a cash buffer and thinking in years, not quarters.

+16.9%

AI Buildout Chokepoints

@rebecca

I believe AI will reshape the knowledge economy the way machinery reshaped industry, and in this buildout phase the value accrues to whoever controls the physical bottlenecks, not just the headline chip names. So this portfolio spreads across five choke points: power and grid equipment, foundry capacity, networking, memory, and cooling, tilted heaviest toward the constraints that take years to expand. It holds 16 positions with no single one dominating, plus a modest cash reserve to add on the sharp drawdowns this sector tends to serve up.

+13.7%

Personalized Medicine Platform Bet

@jared

I believe personalized medicine, especially mRNA and custom cancer vaccines, moves from a one off Covid story to a standard way of treating disease over the next decade or two. Rather than betting on any single drug winning trials, I anchor the portfolio in the sequencing, lab tools, and manufacturing suppliers that get paid regardless of which vaccine succeeds, then layer in a smaller slice of the platform makers themselves, diversified pharma partners, and diagnostics companies.

+11.0%

Home AI Edge Compute

@nikita

I believe AI inference is moving out of the cloud and into hardware people own, as open-source models keep getting smaller and better. I'm expressing this through device makers shipping AI PCs and consumer GPUs, backed by the memory, storage, and edge silicon that gate local models, plus a small sleeve in the open-model ecosystem. No single position dominates, I keep a 10% cash buffer to add on dips, and I'm running this as a concentrated, two-year view rather than a forever holding.

+9.5%

Medicine 2045

@aweissman

I believe medicine over the next 20 years gets rebuilt from the ground up: genes edited instead of symptoms managed, drugs designed by AI instead of found by trial and error, cancer caught early instead of late. About a quarter of the portfolio anchors this in steady sequencing, lab tools, and surgical platforms that get paid regardless of which cure wins, while smaller positions in gene editing, AI drug discovery, and early detection carry the real transformational upside.

+8.9%

The Knowledge Creation Engine

@akhil

I believe the entities creating the most net new knowledge, and owning what they discover, will compound faster than the broader market over time. So this portfolio pairs the discovery engines themselves, AI labs, drug researchers, frontier science bets, with the toolmakers everyone must pay to do that discovery: instruments, chip design, lithography. It is spread across 16 positions in five sub-themes, mostly large compounders with a few asymmetric bets, plus a cash buffer, built to hold for years since knowledge compounds slowly.

+7.6%

Watts and Wafers

@illscience

I think the market still isn't pricing how much AI compute demand keeps compounding over the next couple of years, and I don't think this is winner-take-all. So instead of betting on one champion, I own the whole chain, tilted toward the choke points: power and wafers, plus the memory and networking everyone needs regardless of whose model wins. It's built concentrated for a two-year window rather than a decade hold, with 10% kept in cash to add on rough days. If demand growth clearly stalls, that's what would change my mind.

+7.3%

Utility Wins: Robots That Solve

@shanemac

I believe utility always beats stated preference: people say they don't want a robot, then call the one that actually solves their problem the best purchase they ever made. So this owns machines already being paid for to solve real problems, surgical robots, home robots, autonomous farming and warehouse fleets, plus a general-purpose bet on working robotic hands, layered with the chips, sensors, and power buildout every one of them depends on.

+4.1%

Robot Parts Inflection

@joshe

I believe consumer robotics is at its dawn, with an inflection coming in the next 2-3 years as humanoids, home robots, and robotaxis move past pilots. Rather than bet on which robot maker wins, I own the suppliers every robot needs: precision motion, perception sensors, robot-brain compute, and power electronics. It's deliberately concentrated in companies already landing design wins, with a cash sleeve kept back to buy dips in these high-beta names, and I'd rethink it if the design wins stop coming.

+3.8%

The Robotics Wave

@stephen

I believe robots move from niche factory lines into warehouses, farms, and hospitals over the next several years, so this basket owns the whole supply chain rather than betting on one robot maker. It pairs established automation leaders with the vision chips, sensors, and motion components every robot needs, plus exposure to the first places robots are landing at scale. It holds a slice of cash and stays diversified across names on purpose, meant to be held for years rather than traded on headlines. I would rethink it if adoption clearly stalls instead of spreading.

+3.4%

The Grid Is the Bottleneck

@homerick

I think the AI buildout will drive years of investment in getting electricity where it needs to go. Companies are already spending, and I think national competition will keep the pressure on. Whatever produces the power, it still needs connections, transformers, substations and controls. I want the businesses building and upgrading that infrastructure. My bet is that delivering reliable electricity becomes one of the durable ways to invest in the AI boom over the next five to ten years.

+3.0%

Smart Apparel Gold Rush

@adam

I believe smart clothing, gear that senses and tracks the body, is about to explode as fashion, tech, and fitness converge, and the winners over the next two to three years will be the companies enabling that shift rather than any single brand that happens to win shelf space. So this basket spreads across the sensor chipmakers, technical materials suppliers, the selling platforms that let designers scale fast, and the fitness-fashion brands with real retail muscle.

+2.2%

Quantified Self Goes Mainstream

@scottbelsky

I believe personal health tracking is about to go fully mainstream, with frequent blood testing, wearable sensors, and personalized protocols becoming normal habits within a couple of years, not niche biohacker stuff. Since the purest plays are private, I built a basket owning the public stack that spend flows through: body sensors and diagnostics as steadier ballast, telehealth and protocol sellers for the punchy momentum side, plus GLP-1 exposure for the wave of newly biomarker-curious people.

+2.0%